Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies

Tumor Development under Combination Treatments with Anti-Angiogenic Therapies

Angiogenic and Cell Therapies

Since Judah Folkman first described the process of angiogenesis in 1971, much has been learned about the cells, the extracellular factors, and the signaling pathways that modulate the angiogenesis, arteriogenesis, and vasculogenesis. Promising preclinical studies led to trials of angiogenic factors and cell therapies for peripheral arterial disease (PAD) in the last 2 decades. Early stage trial...

Anti-angiogenic therapies in brain metastases

Brain metastases are a major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising preventive as well as therapeutic approach. The current review will summarize the cur...

Anti-angiogenic therapies for malignant pleural mesothelioma.

INTRODUCTION Malignant pleural mesothelioma (MPM) is a disease with a dismal prognosis. Currently available treatments have modest results. Therefore, new agents and new treatment strategies are eagerly awaited by patients and clinicians. Preclinical and clinical studies have shown that angiogenesis plays a very important role in MPM. Therefore, a great hope has been placed in the use of anti-a...

How to develop better screens for anti-cancer therapies?

The clinical efficacy of chemotherapy relies in part on its ability to potentiate anti-tumor immune responses. Recent work shows that several chemotherapeutic drugs induce intra-tumoral expression of lymphocyte-attracting chemokines, leading to clinical responses. Here, we argue that such knowledge should be used to screen for novel anti-tumor treatments.